Actuate Therapeutics' (NASDAQ:ACTU - Get Free Report) lock-up period is set to end on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its IPO on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Actuate Therapeutics Stock Performance
NASDAQ ACTU traded down $0.62 during mid-day trading on Thursday, hitting $8.82. The company's stock had a trading volume of 10,573 shares, compared to its average volume of 34,466. Actuate Therapeutics has a 52-week low of $5.51 and a 52-week high of $11.73. The company has a fifty day moving average price of $8.48.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ACTU. Freestone Capital Holdings LLC acquired a new stake in Actuate Therapeutics in the fourth quarter valued at approximately $80,000. KG&L Capital Management LLC acquired a new stake in shares of Actuate Therapeutics during the third quarter valued at about $89,000. Sigma Planning Corp acquired a new position in shares of Actuate Therapeutics in the fourth quarter worth about $128,000. Finally, Northwestern University purchased a new position in Actuate Therapeutics in the third quarter valued at about $207,000.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Further Reading
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
